Online citations, reference lists, and bibliographies.

Pancreatic Adenocarcinoma: Number Of Positive Nodes Allows To Distinguish Several N Categories.

Oliver Strobel, Ulf Hinz, Alexander Gluth, Thomas P. Hank, Thilo Hackert, Frank W. Bergmann, Jens Werner, Markus W. Büchler
Published 2015 · Medicine
Cite This
Download PDF
Analyze on Scholarcy
Share
OBJECTIVE To determine the prognostic value of PLN and LNR based on a large series with standardized lymphadenectomy and pathological workup. BACKGROUND Lymph node (LN) involvement is a major prognostic factor in pancreatic adenocarcinoma. However, the distinction N0/N1 is not sufficient to accurately predict prognosis. To improve prognostic accuracy in N1 tumors, different LN parameters have been tested. Previous studies were based on series with variable numbers of examined lymph nodes (ELN) and came to inconsistent conclusions as to the value of the number of positive lymph nodes (PLN) and the lymph node ratio (LNR). METHODS 811 patients who underwent pancreatoduodenectomy for pancreatic adenocarcinoma between October 2001 and June 2012 were identified from a prospective database. Clinicopathological parameters included LN status (N0/N1), ELN, PLN, and LNR. Univariate and multivariate survival analyses were performed. RESULTS The median number of ELN was 24 (interquartile range: 18-32). By univariate analysis, both PLN and LNR were significantly associated with survival in N1 tumors. However, by multivariate analysis, only the number of PLN was confirmed as independent predictor of survival. Median survival in patients with only 1 PLN was 31.1 months and comparable to the survival in N0 (33.2 months). With increasing numbers of PLN median survival significantly decreased (2-3 PLN: 26.1 months, 4-7 PLN: 21.9 months, ≥8 PLN: 18.3 months, P < 0.0001). CONCLUSIONS This study demonstrates that, based on high numbers of ELN, PLN is superior to LNR in predicting survival and allows to distinguish several N-categories that improve prognostic accuracy in LN-positive resectable pancreatic adenocarcinoma.
This paper references
10.1007/s11605-012-1974-7
N0/N1, PNL, or LNR? The Effect of Lymph Node Number on Accurate Survival Prediction in Pancreatic Ductal Adenocarcinoma
Nakul P. Valsangkar (2012)
The metastatic/examined lymph node ratio is an important prognostic factor after pancreaticoduodenectomy for pancreatic adenocarcinoma.
Adam C Berger (2004)
10.1038/nrclinonc.2013.66
Advanced-stage pancreatic cancer: therapy options
Jens Werner (2013)
10.1016/j.jamcollsurg.2010.03.037
Number of metastatic lymph nodes, but not lymph node ratio, is an independent prognostic factor after resection of pancreatic carcinoma.
Y. Murakami (2010)
10.1097/01.mpa.0000235306.96486.2a
The Ratio of Metastatic/Resected Lymph Nodes is an Independent Prognostic Factor in Patients With Node-positive Pancreatic Head Cancer
Marek Sierzega (2006)
10.1007/978-1-4757-3656-4
AJCC Cancer Staging Manual
M. B. Amin (2002)
10.1159/000018741
Locoregional Dissemination and Extended Lymphadenectomy in Pancreatic Cancer
Laureano Fernández‐Cruz (1999)
10.1245/s10434-006-9016-x
Extent of Lymph Node Retrieval and Pancreatic Cancer Survival: Information from a Large US Population Database
R. Schwarz (2006)
10.1097/SLA.0b013e31821fd334
Pancreatic Cancer Surgery in the New Millennium: Better Prediction of Outcome
Werner Hartwig (2011)
10.1001/archsurg.142.8.767
Accuracy of staging node-negative pancreas cancer: a potential quality measure.
James S Tomlinson (2007)
10.1016/j.ijrobp.2010.07.1993
The influence of total nodes examined, number of positive nodes, and lymph node ratio on survival after surgical resection and adjuvant chemoradiation for pancreatic cancer: a secondary analysis of RTOG 9704.
Timothy N. Showalter (2011)
10.1148/radiology.207.1.66
TNM Classification of Malignant Tumors. 5th ed
R. Szucs (1998)
10.1159/000140961
Preoperative CA19-9 Levels and Lymph Node Ratio Are Independent Predictors of Survival in Patients with Resected Pancreatic Ductal Adenocarcinoma
Robert Anthony Smith (2008)
10.1245/s10434-008-9839-8
Most Pancreatic Cancer Resections are R1 Resections
I. Esposito (2008)
10.1002/bjs.5397
Redefining the R1 resection in pancreatic cancer.
C. Verbeke (2006)
10.1002/jso.22013
Role of the lymph node ratio in pancreatic ductal adenocarcinoma. Impact on patient stratification and prognosis.
M. La Torre (2011)
10.1245/s10434-007-9587-1
Impact of Total Lymph Node Count and Lymph Node Ratio on Staging and Survival after Pancreatectomy for Pancreatic Adenocarcinoma: A Large, Population-Based Analysis
Mark B. Slidell (2007)
10.1097/MPA.0b013e31816074c9
The Impact of Lymph Node Number on Survival in Patients With Lymph Node-Negative Pancreatic Cancer
Minia Hellan (2008)
10.1007/s11605-012-1853-2
Number of Lymph Nodes Evaluated: Prognostic Value in Pancreatic Adenocarcinoma
M. Huebner (2012)
10.1016/j.ejso.2011.12.020
Metastatic lymph node ratio as an important prognostic factor in pancreatic ductal adenocarcinoma.
Sian M Robinson (2012)
10.1097/COC.0b013e31826e0570
Adjuvant Radiotherapy and Lymph Node Status for Pancreatic Cancer: Results of a Study From the Surveillance, Epidemiology, and End Results (SEER) Registry Data
Krisha J. Opfermann (2014)
10.1007/s11605-009-1096-z
Does the Mechanism of Lymph Node Invasion Affect Survival in Patients with Pancreatic Ductal Adenocarcinoma?
Ioannis T. Konstantinidis (2009)
10.1007/s11605-007-0243-7
Prognostic Significance of Pathologic Nodal Status in Patients with Resected Pancreatic Cancer
Michael G. House (2007)
10.1007/s11605-009-0919-2
The Lymph Node Ratio is the Strongest Prognostic Factor after Resection of Pancreatic Cancer
H. Riediger (2009)
10.1016/j.surg.2006.12.013
Prognostic relevance of lymph node ratio following pancreaticoduodenectomy for pancreatic cancer.
T. Pawlik (2007)



This paper is referenced by
10.1097/SLA.0000000000002432
Prognostic Value of Resection Margin Involvement After Pancreaticoduodenectomy for Ductal Adenocarcinoma: Updates From a French Prospective Multicenter Study
Jean Robert Delpero (2017)
10.1016/j.pharmthera.2015.08.006
State of the art and future directions of pancreatic ductal adenocarcinoma therapy.
Cindy Neuzillet (2015)
10.1002/9781118781166.CH24
Indications and contraindications for laparoscopic pancreas surgery
Hanno Niess (2016)
10.7150/jca.26187
A Refined Staging Model for Resectable Pancreatic Ductal Adenocarcinoma Incorporating Examined Lymph Nodes, Location of Tumor and Positive Lymph Nodes Ratio
Yunda Song (2018)
10.1002/bjs.10316
Incidence, risk factors and clinical implications of chyle leak after pancreatic surgery
Oliver Strobel (2017)
10.1245/s10434-017-6237-0
T-Helper 1 Immune Response in Metastatic Lymph Nodes of Pancreatic Ductal Adenocarcinoma: A Marker For Prolonged Survival
E. Nizri (2017)
10.1016/j.pan.2018.04.010
Pathology assessment of pancreatic cancer following neoadjuvant treatment: Time to move on.
C. Verbeke (2018)
10.1016/J.EJRAD.2019.04.007
Predicting lymph node metastasis in pancreatobiliary cancer with magnetic resonance imaging: A prospective analysis.
Ju Hee Lee (2019)
10.1002/bjs.10472
Staging of pancreatic cancer based on the number of positive lymph nodes
Ignazio Tarantino (2017)
10.3748/wjg.v23.i24.4399
Para-aortic node involvement is not an independent predictor of survival after resection for pancreatic cancer
Cosimo Sperti (2017)
10.1038/s41598-017-08165-w
Para-aortic lymph node metastases in pancreatic cancer should not be considered a watershed for curative resection
Sebastian Hempel (2017)
10.1016/j.ejso.2019.01.018
Determining the optimal number of examined lymph nodes for accurate staging of pancreatic cancer: An analysis using the nodal staging score model.
J. Hua (2019)
Surgical methods in treating pancreatic tumours 180420
Johanna Hansson Wennerblom (2018)
10.1177/1066896919886057
Prognostic Implication of pN Stage Subdivision Using Metastatic Lymph Node Ratio in Resected Pancreatic Ductal Adenocarcinoma
Jung-Soo Pyo (2019)
10.1186/s12893-017-0311-1
Prognostic role of nodal ratio, LODDS, pN in patients with pancreatic cancer with venous involvement
G. Ramacciato (2017)
10.1002/bjs.10221
Outcomes after extended pancreatectomy in patients with borderline resectable and locally advanced pancreatic cancer.
Werner Hartwig (2016)
10.1007/s11605-018-3995-3
Optimal Extent of Superior Mesenteric Artery Dissection during Pancreaticoduodenectomy for Pancreatic Cancer: Balancing Surgical and Oncological Safety
Yosuke Inoue (2018)
Characteristicsof10-YearSurvivors ofPancreaticDuctalAdenocarcinoma
A. Paniccia (2015)
10.1186/s12885-018-4901-9
Impact of tumor size on survival of patients with resected pancreatic ductal adenocarcinoma: a systematic review and meta-analysis
Debang Li (2018)
10.3748/wjg.v25.i46.6752
Mesenterico-portal vein invasion should be an important factor in TNM staging for pancreatic ductal adenocarcinoma: Proposed modification of the 8th edition of the American Joint Committee on Cancer staging system
Hong-Yu Chen (2019)
10.1186/s12957-016-0983-5
Number of evaluated lymph nodes and positive lymph nodes, lymph node ratio, and log odds evaluation in early-stage pancreatic ductal adenocarcinoma: numerology or valid indicators of patient outcome?
G. Lahat (2016)
10.5146/tjpath.2017.01414
Do the Well Known Prognostic Parameters in Pancreatic Ductal Adenocarcinoma Really Reflect Survival?
Sonay Kuş Öztürk (2018)
10.1016/j.ejso.2020.02.002
Prognostic value of 18FDG PET/CT volumetric parameters in the survival prediction of patients with pancreatic cancer.
Eyas Mohamed (2020)
10.1089/pancan.2019.0013
Portal-Mesenteric Vein Resection in Borderline Pancreatic Cancer; 33 Month-Survival in Patients with Good Performance Status
Gregory G. Tsiotos (2019)
10.2217/fon-2016-0010
Pancreatic cancer: yesterday, today and tomorrow.
Daniel Ansari (2016)
10.1097/SLA.0000000000001763
Multi-institutional Validation Study of the American Joint Commission on Cancer (8th Edition) Changes for T and N Staging in Patients With Pancreatic Adenocarcinoma
P. Allen (2017)
10.1097/SLA.0000000000001921
Pancreatic Ductal Adenocarcinoma: A New TNM Staging System is Needed!
Stefano Crippa (2017)
10.1016/j.pan.2017.03.008
Systematic review of the clinical significance of lymph node micrometastases of pancreatic adenocarcinoma following surgical resection.
Sae Byeol Choi (2017)
10.1038/nrclinonc.2016.127
Pancreatic cancer: Clinical practice guidelines — what is the evidence?
Oliver Strobel (2016)
10.3892/ol.2017.6549
Degree of desmoplasia in metastatic lymph node lesions is associated with lesion size and poor prognosis in pancreatic cancer patients.
H. Nakayama (2017)
10.3892/ol.2017.7539
High expression of RACK1 is associated with poor prognosis in patients with pancreatic ductal adenocarcinoma
Hailin Han (2018)
10.18632/oncotarget.18714
Cbl-b predicts postoperative survival in patients with resectable pancreatic ductal adenocarcinoma.
Qian Dong (2017)
See more
Semantic Scholar Logo Some data provided by SemanticScholar